Table 31: Antidepressants (also see prescribing information)		
→ Including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), trazodone, bupropion, and monoamine oxidase inhibitors (MAOIs)		
Class or Drug	**Mechanism of Action**	**Clinical Comments**
• NRTIs • Dolutegravir (DTG) • Bictegravir (BIC) • Cabotegravir (CAB) • Raltegravir (RAL) • Rilpivirine (RPV) • Doravirine (DOR)	No significant interactions reported.	No dose adjustments are necessary.
• Elvitegravir (EVG), boosted • Boosted PIs	**Trazodone:** Concomitant use may increase trazodone concentrations.	**Trazodone:** Monitor for antidepressant and/or sedative effects.
• Efavirenz (EFV) • Etravirine (ETR)	• **Trazodone:** EFV and ETR may decrease trazodone concentrations. • **Bupropion:** – EFV may induce CYP2B6, the enzyme that is primarily responsible for bupropion metabolism. – No significant interactions are expected with ETR.	• **Trazodone:** Monitor for antidepressant and/or sedative effects. • **Bupropion:** Monitor for clinical effect and increase as needed, but do not exceed recommended maximum dose.
Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.		